Pizotifen (BC 105) in migraine prophylaxis
- 1 January 1975
- journal article
- clinical trial
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 3 (2), 68-71
- https://doi.org/10.1185/03007997509113649
Abstract
Pizotifen, an antaminic, was investigated in a double-blind placebo controlled trial to evaluate its efficacy in migraine prophylaxis. It was found to be and effective prophylactic in a proportion of migraine patients, reducing the frequency as well as the severity of headaches. Some patients showed weight gain. Several patients have continued treatment for up to 2 years with good control of their migraine and a reduction in the amount of medicament required for the acute attack.Keywords
This publication has 8 references indexed in Scilit:
- PROPHYLACTIC TREATMENT OF CLUSTER HEADACHE WITH A NEW SEROTONIN ANTAGONIST, BC 105Acta Neurologica Scandinavica, 2009
- BC‐105‐A NEW PROPHYLACTIC AGENT FOR MIGRAINE ‐ FOUR YEARS' EXPERIENCE IN SEVENTY‐FIVE PATIENTSHeadache: The Journal of Head and Face Pain, 1973
- LONG‐TIME EFFECT AND TOLERANCE DURING PROPHYLACTIC TREATMENT OF MIGRAINE WITH A BENZO‐CYCLOHEPTATHIOPHENE DERIVATIVE, PIZOTIFENHeadache: The Journal of Head and Face Pain, 1973
- A COMPARISON BETWEEN BC 105 AND METHYSERGIDE IN THE PROPHYLAXIS OF MIGRAINEActa Neurologica Scandinavica, 1972
- Comparative Trial of Serotonin Antagonists in the Management of MigraineBMJ, 1970
- APPRAISAL OF BC-105 IN MIGRAINE PROPHYLAXISActa Neurologica Scandinavica, 1969
- An Antaminic Drug, BC 105, in the Prophylaxis of MigraineInternational Archives of Allergy and Immunology, 1967
- Special CommunicationPublished by American Medical Association (AMA) ,1962